An act relating to psychedelic therapy and clinical drug development trials

H 859 establishes a Psychedelic Therapy Advisory Board to review research on psychedelic therapy's benefits for mental health and substance use disorders, and to recommend state programs allowing therapeutic use of psychedelics. The bill requires Vermont's Department of Health to contract with a Vermont entity to conduct clinical drug development trials specifically for ibogaine - a treatment being studied for substance use disorders and trauma. The Advisory Board will assess public health impacts, monitor other states' programs, and propose pilot projects for psychedelic-assisted therapy in end-of-life care or for mental health conditions. This directly affects Vermont's healthcare system, mental health providers, and individuals seeking treatment for conditions resistant to current therapies.